Evaluation of Immunogenicity of Novel Isoform of EG95 (EG95-5G1) From Echinococcus granulosus in BALB/C Mice
Background: Echinococcosis is a zoonotic parasitic disease of humans and various herbivorous domestic animals transmitted by the contact with domestic and wild carnivores,mainly dogs and foxes. The aim of this study is the production, purification and evaluation immunogenicity of new construction of EG95 protein.
Methods: The recombinant plasmid pET32-a+ used for Eg95 expression was constructed with the EG95 gene of Echinococcus granulosus fused with the thioredoxin tag.This recombinant clone was over expressed in Escherichia coli BL-21 (DE-3). The expressed fusion protein was found almost entirely in the insoluble form (inclusion bodies) in cell lysate. The purification was performed under denaturing conditions in the presence of 8M urea by Ni–NTA column and dialysis. The purified recombinant proteins were confirmed with western blot analysis using polyclonal antiserum. To find out the immunogenicity of the purified protein, the BALB/c mice(10mice/group) were immunized by injecting 20 μg rEG95 protein formulated in Freund’s and alum adjuvant.
Results: Immunization of mice with rEG95 using CFA/IFA and alum adjuvant generated high level of total antibody. In proliferation assay, the lymphocytes were able to mount a strong proliferative response with related production of IFN-ɣ, IL-12 and TNF-α but with low secretion of either IL-4 or IL-10. The humoral and cellular immune responses against rEG95 suggested a mixed Th1/Th2 response with high intensity toward Th1.
Conclusion: Our findings suggest that new construct of rEG95 formulated with CFA/IFA and alum adjuvant elicited strong cellular and humoral responses supporting further development of this vaccine candidate
Moro P, Schantz PM. Echinococcosis: a review. Int J Infec Dis. 2009;13(2):125-33.
WHO. The control of neglected zoonotic diseases: A route to poverty alleviation. Report of a joint WHO/DFID-AHP meeting, 20 and 21 September 2005, WHO Headquarters, Geneva, with the participation of FAO and OIE. 2009.
McManus DP, Zhang W, Li J, Bartley PB. Echinococcosis. Lancet. 2003;362(9392):1295-304.
Heath D, Yang W, Li T, Xiao Y, Chen X, Huang Y, et al. Control of hydatidosis. Parasitol Int. 2006;55:S247-S52.
Jenkins D, Romig T, Thompson R. Emergence/re-emergence of Echinococcus spp.—a global update. Int J Parasitol. 2005;35(11):1205-19.
Dakkak A. Echinococcosis/hydatidosis: a severe threat in Mediterranean countries. Vet Parasitol. 2010;174(1):2-11.
Budke CM, Deplazes P, Torgerson PR. Global socioeconomic impact of cystic echinococcosis. Emerg Infect Dis. 2006;12(2):296.
Budke CM, Jiamin Q, Zinsstag J, Qian W, Torgerson PR. Use of disability adjusted life years in the estimation of the disease burden of echinococcosis for a high endemic region of the Tibetan plateau. Am J Trop Med Hyg. 2004;71(1):56-64.
Torgerson PR, Oguljahan B, Muminov AE, Karaeva RR, Kuttubaev OT, Aminjanov M, et al. Present situation of cystic echinococcosis in Central Asia. Parasitol Int. 2006;55:S207-S12.
Yang YR, Williams GM, Craig PS, McManus DP. Impact of increased economic burden due to human echinococcosis in an underdeveloped rural community of the People's Republic of China. PLoS Negl Trop Dis. 2010;4(9):e801.
Craig PS, Larrieu E. Control of cystic echinococcosis/hydatidosis: 1863–2002. Adv Parasitol. 2006;61:443-508.
Gauci C, Heath D, Chow C, Lightowlers MW. Hydatid disease: vaccinology and development of the EG95 recombinant vaccine. Expert Rev Vaccines. 2005;4(1):103-12.
Haag KL, Gottstein B, Ayala FJ. The EG95 antigen of Echinococcus spp. contains positively selected amino acids, which may influence host specificity and vaccine efficacy. PloS ONE. 2009;4(4):e5362.
Chow C, Gauci CG, Cowman AF, Lightowlers MW. A gene family expressing a host-protective antigen of Echinococcus granulosus. Mol Biocheml Parasitol. 2001;118(1):83-8.
Chow C, Gauci CG, Cowman AF, Lightowlers MW. Echinococcus granulosus: oncosphere-specific transcription of genes encoding a host-protective antigen. Exp Parasitol. 2004;106(3):183-6.
Alvarez Rojas CA, Gauci CG, Nolan MJ, Harandi MF, Lightowlers MW. Characterization of the eg95 gene family in the G6 genotype of Echinococcus granulosus. Mol Biochem Parasitol. 2012;183(2):115-21.
Alvarez Rojas C, Gauci CG, Lightowlers MW. Antigenic differences between the EG95‐related proteins from Echinococcus granulosus G1 and G6 genotypes: implications for vaccination. ParasiteImmunol. 2013;35(2):99-102.
Lightowlers M, Jensen O, Fernandez E, Iriarte J, Woollard D, Gauci C, et al. Vaccination trials in Australia and Argentina confirm the effectiveness of the EG95 hydatid vaccine in sheep. Int J Parasitol. 1999;29(4):531-4.
Heath D, Lightowlers M. Vaccination on hydatidology—state of the art. Arch Int Hidatid. 1997;33:14-6.
Craig PS, McManus DP, Lightowlers MW, Chabalgoity JA, Garcia HH, Gavidia CM, et al. Prevention and control of cystic echinococcosis. Lancet Infect Dis. 2007;7(6):385-94.
Sarvi S, Dalimi A, Ghafarifar F. Molecular Cloning and Expression of EG95 Gene of Iranian Isolates of Echinococcus granulosus. Iran J Parasitol. 2012;7(2):1-7.
Haag KL, Gottstein B, Ayala FJ. Taeniid history, natural selection and antigenic diversity: evolutionary theory meets helminthology. Trends Parasitol. 2008;24(2):96-102.
Bergquist R, Whittaker M. Control of neglected tropical diseases in Asia Pacific: implications for health information priorities. Infect Dis Poverty. 2012;1(1):3.
Ma X, Zhou X, Zhu Y, Li Y, Wang H, Mamuti W, et al. The prediction of T and B combined epitope and tertiary structure of the Eg95 antigen of Echinococcus granulosus. Exp Ther Med. 2013;6(3):657-62.
Hewitson JP, Maizels RM. Vaccination against helminth parasite infections. Expert Review of Vaccines. 2014;13(4):473-87.
Zhang W, Li J, You H, Zhang Z, Turson G, Loukas A, et al. Short report: Echinococcus granulosus from Xinjiang, PR China: cDNAs encoding the EG95 vaccine antigen are expressed in different life cycle stages and are conserved in the oncosphere. Am J Trop Med Hyg. 2003;68(1):40-3.
Bonay P, Gonz lez LM, Ben tez L, Foster M, Harrison LJ, Parkhouse RME, et al. Genomic and functional characterisation of a secreted antigen of Taenia saginata oncospheres. Mol Biochem Parasitol. 2002;121(2):269-73.
Bork P, Doolittle RF. Fibronectin type III modules in the receptor phosphatase CD45 and tapeworm antigens. Protein Sci. 1993;2(7):1185-7.
Lightowlers MW. Vaccines against cysticercosis and hydatidosis: foundations in taeniid cestode immunology. Parasitol Int. 2006;55:S39-S43.
Woollard DJ, Gauci CG, Heath DD, Lightowlers MW. Protection against hydatid disease induced with the EG95 vaccine is associated with conformational epitopes. Vaccine. 2000; 19(4):498-507.
Bork P, Doolittle RF. Proposed acquisition of an animal protein domain by bacteria. Proc Natl Acad Sci U S A. 1992;89(19):8990-4.
Chiarella P, Edelmann B, Fazio VM, Sawyer AM, de Marco A. Antigenic features of protein carriers commonly used in immunisation trials. Biotechnol Let. 2010;32(9):1215-21.
LaVallie ER, DiBlasio EA, Kovacic S, Grant KL, Schendel PF, McCoy JM. A thioredoxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm. Nat Biotechnol. 1993;11(2):187-93.
Chow C, Gauci CG, Vural G, Jenkins DJ, Heath DD, Rosenzvit MC, et al. Echinococcus granulosus:Variability of the host-protective EG95 vaccine antigen in G6 and G7 genotypic variants. Exp Parasitol. 2008;119(4):499-505.
Suzuki Y. Negative selection on neutralization epitopes of poliovirus surface proteins:implications for prediction of candidate epitopes for immunization. Gene. 2004;328:127-33.
|Issue||Vol 9 No 4 (2014)|
|EG95 protein Echinococcus granulosus Immunogenicity New isoform|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|